Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Cybin Inc (HELP)

Cybin Inc (HELP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity FinancialNewsMedia - Tue Jun 30, 8:00AM CDT

EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:DFTX),(NASDAQ:CMPS),(NASDAQ:GHRS),(NYSE:JNJ) EQNX::TICKER_END

HELP : 6.02 (-0.17%)
CMPS : 13.20 (+1.62%)
GHRS : 26.54 (-1.30%)
JNJ : 266.77 (-0.18%)
DFTX : 45.42 (+2.11%)
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity GlobeNewswire - Tue Jun 30, 8:00AM CDT

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The way Major Depressive Disorder (MDD) is treated is changing faster than it has in years. For decades, most patients...

HELP : 6.02 (-0.17%)
CMPS : 13.20 (+1.62%)
GHRS : 26.54 (-1.30%)
JNJ : 266.77 (-0.18%)
DFTX : 45.42 (+2.11%)
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results GlobeNewswire - Mon Jun 29, 6:40AM CDT

- Recently closed $50 million underwritten offering reinforces strong institutional investor conviction and bolsters balance sheet for execution of second Phase 3 HLP003 trial 1 , 2 ,3 , EMBRACE,...

HELP : 6.02 (-0.17%)
HELP.NE : 8.3000 (-1.89%)
Cybin's Phase Three Depression Data Could Rewrite Investor Expectations by Year End Barchart - Sun Jun 28, 4:00PM CDT

Barchart Research What to Expect from HELP Earnings HELP Generated June 26, 2026 Current Price $6.50 EPS Estimate $$-1.04 Consensus Rating Strong Buy Average Move 3.94% Cybin's Phase Three Depression Data...

HELP : 6.02 (-0.17%)
Cybin's Phase Three Depression Data Could Rewrite Investor Expectations by Year End Barchart - Sat Jun 27, 4:00PM CDT

Barchart Research What to Expect from HELP Earnings HELP Generated June 26, 2026 Current Price $6.50 EPS Estimate $$-1.04 Consensus Rating Strong Buy Average Move 3.94% Cybin's Phase Three Depression Data...

HELP : 6.02 (-0.17%)
Cybin's Phase Three Depression Data Could Rewrite Investor Expectations by Year End Barchart - Fri Jun 26, 4:01PM CDT

Barchart Research What to Expect from HELP Earnings HELP Generated June 26, 2026 Current Price $6.50 EPS Estimate $$-1.04 Consensus Rating Strong Buy Average Move 3.94% Cybin's Phase Three Depression Data...

HELP : 6.02 (-0.17%)
Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering GlobeNewswire - Thu Jun 25, 8:27AM CDT

NEW YORK and TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “ Company ” or “ Helus Pharma ”), a clinical stage pharmaceutical company committed...

HELP : 6.02 (-0.17%)
HELP.NE : 8.3000 (-1.89%)
FNM News Break: Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress FinancialNewsMedia - Wed Jun 24, 8:05AM CDT

EQNX::TICKER_START (NASDAQ:HELP) EQNX::TICKER_END

HELP : 6.02 (-0.17%)
Helus Pharma™ Announces US$50 Million Underwritten Offering GlobeNewswire - Wed Jun 24, 5:01AM CDT

NEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “ Company ” or “ Helus Pharma ”), a clinical stage pharmaceutical company committed...

HELP : 6.02 (-0.17%)
HELP.NE : 8.3000 (-1.89%)
Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress GlobeNewswire - Wed Jun 24, 5:00AM CDT

- APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorder (“MDD”) is progressing as planned and has surpassed 86% enrollment - - Phase 2 HLP003 data...

HELP : 6.02 (-0.17%)
HELP.NE : 8.3000 (-1.89%)

Barchart Exclusives

Broadcom’s $30 Billion Jackpot: Why Apple Admitting Defeat Makes This Stock an Automatic Buy Barchart - 5 minutes ago
Broadcom's $30 billion Apple deal removes its biggest long-term risk while strengthening its AI growth strategy. The agreement gives investors greater confidence in the chipmaker's future earnings and cash flow. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.